In human breast cancer cells METAP1 or METAP2 knockdown in combination with BEZ treatment reduced cell growth significantly better than knockdown alone but not significantly better than PI3K-inhibitor treatment alone, comparable with shRenilla control cells (Figure 5C). This evidence concerns the gene METAP2 and breast cancer.